Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Miles

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Nature Reviews. Clinical Oncology|September 3, 2010
Rechallenging with anthracyclines and taxanes in metastatic breast cancerCarlo Palmieri, Jonathan Krell, Colin R James, et al.
Journal of Mammary Gland Biology and Neoplasia|December 5, 2002
MUC1 and the immunobiology of cancerJoyce Taylor-Papadimitriou, Joy M Burchell, Timothy Plunkett, et al.
Journal of Cancer|August 29, 2013
Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized TrialNuhad K Ibrahim, James L Murray, Dapeng Zhou, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Journal of Food Protection|June 15, 2011
A survey of total hydrocyanic acid content in ready-to-eat cassava-based chips obtained in the Australian market in 2008David Miles, Edward Jansson, My Chi Mai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trialsDavid Miles, Nadia Harbeck, Bernard Escudier, et al.
Breast Cancer Research and Treatment|April 3, 2010
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerValentina Guarneri, David Miles, Nicholas Robert, et al.
Cancer|November 14, 2013
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancerManfred Welslau, Veronique Diéras, Joo-Hyuk Sohn, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Nature Reviews. Clinical Oncology|September 3, 2010
Rechallenging with anthracyclines and taxanes in metastatic breast cancerCarlo Palmieri, Jonathan Krell, Colin R James, et al.
Journal of Mammary Gland Biology and Neoplasia|December 5, 2002
MUC1 and the immunobiology of cancerJoyce Taylor-Papadimitriou, Joy M Burchell, Timothy Plunkett, et al.
Journal of Cancer|August 29, 2013
Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized TrialNuhad K Ibrahim, James L Murray, Dapeng Zhou, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Journal of Food Protection|June 15, 2011
A survey of total hydrocyanic acid content in ready-to-eat cassava-based chips obtained in the Australian market in 2008David Miles, Edward Jansson, My Chi Mai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trialsDavid Miles, Nadia Harbeck, Bernard Escudier, et al.
Breast Cancer Research and Treatment|April 3, 2010
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerValentina Guarneri, David Miles, Nicholas Robert, et al.
Cancer|November 14, 2013
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancerManfred Welslau, Veronique Diéras, Joo-Hyuk Sohn, et al.
Pageof 6